PROGRAMME
From global therapeutics to personalized medicine: what changed over the last 15 years?
>> Central European Time - CET (Paris) <<
Thursday, April 29th, 2021
3:00 – 3:05 pm |
Introduction of the WorldMEN meeting |
3:05 – 4:30 pm |
Session 1: MTC AND MEN2 |
3:05 pm |
State of the art: unmet needs and sessions introduction
Each talk will be pre-recorded (20 minutes), presented as a 5 minutes live summary followed by 5 minutes live discussion |
3:20 pm |
Predictive factors of outcome in MEN2B |
3:30 pm |
MicroRNAs and MTC |
3:40 pm |
Quality of life in MEN2 |
3:50 pm |
Anti-RET and MTC |
4:00 pm |
Round table / Discussion / Perspectives |
4:30 – 4:50 pm |
Industry Sponsored Lecture |
4:50 – 5:00 pm |
Break |
5:00 – 6:30 pm |
Session 2: Pheochromocytoma and paraganglioma |
5:00 pm |
State of the art: unmet needs and sessions introduction Each talk will be pre-recorded (20 minutes), presented as a 5 minutes live summary followed by 5 minutes live discussion |
5:15 pm |
MicroRNAs and Pheo/PGL |
5:25 pm |
Targeted therapy: Insights from invitro |
5:35 pm |
Update on malignant pheo |
5:45 pm |
177Lu-Dotatate in inoperable pheo/pgl |
5:55 pm |
An update from the guidelines on pheo/pgl |
6:05 pm |
Round table / Discussion / Perspectives |
6:30 – 6:50 pm |
Industry Sponsored Lecture |
Friday, April 30th, 2021
3:00 – 4:30 pm |
Session 3: Neuro-endocrine tumors |
3:00 pm |
State of the art: unmet needs and sessions introduction
Each talk will be pre-recorded (20 minutes), presented as a 5 minutes live summary followed by 5 minutes live discussion |
3:15 pm |
Bronchial and thymic carcinoids |
3:25 pm |
Precision oncological approaches in NETs |
3:35 pm |
Immunotherapy in NETs |
3:45 pm |
New isotopes in NETs |
3:55 pm |
Round table / Discussion / Perspectives |
4:30 – 4:50 pm |
Industry Sponsored Lecture |
4:50 – 5:00 pm |
Break |
5:00 – 6:45 pm |
Session 4: MEN1 |
5:00 pm |
State of the art: unmet needs and sessions introduction
Except for the guidelines, each talk will be pre-recorded (20 minutes), presented as a 5 minutes live summary followed by 5 minutes live discussion |
5:15 pm |
Exendin-4 in insulinoma |
5:25 pm |
Pediatrics in MEN1 |
5:35 pm |
Genetics and MEN1 |
5:45 – 6:45 pm |
MEN1 Guidelines: |
5:45 pm |
Update on MEN1 Guidelines |
6:15 pm |
Discussion on the Guidelines |
6:45 – 7:05 pm |
Industry Sponsored Lecture |
7:05 – 7:15 pm |
Conclusions |